Multilayered defense in HLA-B51-associated HIV viral control
Polymorphism in the HLA region of a chromosome is the major source of host genetic variability in HIV-1 outcome, but there is limited understanding of the mechanisms underlying the beneficial effect of protective class I alleles such as HLA-B57, -B27, and -B51. Taking advantage of a unique cohort in...
Gespeichert in:
Veröffentlicht in: | The Journal of immunology (1950) 2011-07, Vol.187 (2), p.684-691 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 691 |
---|---|
container_issue | 2 |
container_start_page | 684 |
container_title | The Journal of immunology (1950) |
container_volume | 187 |
creator | Zhang, YongHong Peng, YanChun Yan, HuiPing Xu, Keyi Saito, Masumichi Wu, Hao Chen, XinYue Ranasinghe, Srinika Kuse, Nozomi Powell, Tim Zhao, Yan Li, WeiHua Zhang, Xin Feng, Xia Li, Ning Leligdowicz, Aleksandra Xu, XiaoNing John, Mina Takiguchi, Masafumi McMichael, Andrew Rowland-Jones, Sarah Dong, Tao |
description | Polymorphism in the HLA region of a chromosome is the major source of host genetic variability in HIV-1 outcome, but there is limited understanding of the mechanisms underlying the beneficial effect of protective class I alleles such as HLA-B57, -B27, and -B51. Taking advantage of a unique cohort infected with clade B' HIV-1 through contaminated blood, in which many variables such as the length of infection, the infecting viral strain, and host genetic background are controlled, we performed a comprehensive study to understand HLA-B51-associated HIV-1 control. We focused on the T cell responses against three dominant HLA-B51-restricted epitopes: Gag327-345(NI9) NANPDCKTI, Pol743-751(LI9) LPPVVAKEI, and Pol283-289(TI8) TAFTIPSI. Mutations in all three dominant epitopes were significantly associated with HLA-B51 in the cohort. A clear hierarchy in selection of epitope mutations was observed through epitope sequencing. L743I in position 1 of epitope LI9 was seen in most B51(+) individuals, followed by V289X in position 8 of the TI8, and then, A328S, in position 2 of the NI9 epitope, was also seen in some B51(+) individuals. Good control of viral load and higher CD4(+) counts were significantly associated with at least one detectable T cell response to unmutated epitopes, whereas lower CD4(+) counts and higher viral loads were observed in patients who had developed escape mutations in all three epitopes or who lacked T cell responses specific to these epitope(s). We propose that patients with HLA-B51 benefit from having multiple layers of effective defense against the development of immune escape mutations. |
doi_str_mv | 10.4049/jimmunol.1100316 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3166850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>875718347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-35d125593748970fe70ada4ca8e82ff60478385d5ec7ad128d8aebc72844a1043</originalsourceid><addsrcrecordid>eNqFkTtPwzAUhS0EoqWwM6FsTCnX8TMSQioIaKUiFmC1XMcBV05c4gSp_56gPgQT0x3Od899HITOMYwp0Pxq6aqqq4MfYwxAMD9AQ8wYpJwDP0RDgCxLseBigE5iXAIAh4weo0GGueh5MkTXT51vnddr29giKWxp62gTVyfT-SS9ZTjVMQbjdNur09lb8uUa7RMT6rYJ_hQdldpHe7atI_T6cP9yN03nz4-zu8k8NTQnbUpYgTPGciKozAWUVoAuNDVaWpmVJQcqJJGsYNYI3aOykNoujMgkpRoDJSN0s_FddYvKFsb207VXq8ZVulmroJ36q9TuQ72HL9W_hEsGvcHl1qAJn52NrapcNNZ7XdvQRZUDpQJ4Rv8lpWACS0JFT8KGNE2IsbHlfh8M6icdtUtHbdPpWy5-37Fv2MVBvgHSnYwh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>875718347</pqid></control><display><type>article</type><title>Multilayered defense in HLA-B51-associated HIV viral control</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Zhang, YongHong ; Peng, YanChun ; Yan, HuiPing ; Xu, Keyi ; Saito, Masumichi ; Wu, Hao ; Chen, XinYue ; Ranasinghe, Srinika ; Kuse, Nozomi ; Powell, Tim ; Zhao, Yan ; Li, WeiHua ; Zhang, Xin ; Feng, Xia ; Li, Ning ; Leligdowicz, Aleksandra ; Xu, XiaoNing ; John, Mina ; Takiguchi, Masafumi ; McMichael, Andrew ; Rowland-Jones, Sarah ; Dong, Tao</creator><creatorcontrib>Zhang, YongHong ; Peng, YanChun ; Yan, HuiPing ; Xu, Keyi ; Saito, Masumichi ; Wu, Hao ; Chen, XinYue ; Ranasinghe, Srinika ; Kuse, Nozomi ; Powell, Tim ; Zhao, Yan ; Li, WeiHua ; Zhang, Xin ; Feng, Xia ; Li, Ning ; Leligdowicz, Aleksandra ; Xu, XiaoNing ; John, Mina ; Takiguchi, Masafumi ; McMichael, Andrew ; Rowland-Jones, Sarah ; Dong, Tao</creatorcontrib><description>Polymorphism in the HLA region of a chromosome is the major source of host genetic variability in HIV-1 outcome, but there is limited understanding of the mechanisms underlying the beneficial effect of protective class I alleles such as HLA-B57, -B27, and -B51. Taking advantage of a unique cohort infected with clade B' HIV-1 through contaminated blood, in which many variables such as the length of infection, the infecting viral strain, and host genetic background are controlled, we performed a comprehensive study to understand HLA-B51-associated HIV-1 control. We focused on the T cell responses against three dominant HLA-B51-restricted epitopes: Gag327-345(NI9) NANPDCKTI, Pol743-751(LI9) LPPVVAKEI, and Pol283-289(TI8) TAFTIPSI. Mutations in all three dominant epitopes were significantly associated with HLA-B51 in the cohort. A clear hierarchy in selection of epitope mutations was observed through epitope sequencing. L743I in position 1 of epitope LI9 was seen in most B51(+) individuals, followed by V289X in position 8 of the TI8, and then, A328S, in position 2 of the NI9 epitope, was also seen in some B51(+) individuals. Good control of viral load and higher CD4(+) counts were significantly associated with at least one detectable T cell response to unmutated epitopes, whereas lower CD4(+) counts and higher viral loads were observed in patients who had developed escape mutations in all three epitopes or who lacked T cell responses specific to these epitope(s). We propose that patients with HLA-B51 benefit from having multiple layers of effective defense against the development of immune escape mutations.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>DOI: 10.4049/jimmunol.1100316</identifier><identifier>PMID: 21670313</identifier><language>eng</language><publisher>United States</publisher><subject>Clone Cells ; Cohort Studies ; Cytotoxicity, Immunologic - genetics ; Epitopes, T-Lymphocyte - genetics ; Epitopes, T-Lymphocyte - immunology ; gag Gene Products, Human Immunodeficiency Virus - genetics ; gag Gene Products, Human Immunodeficiency Virus - immunology ; HEK293 Cells ; HIV-1 - genetics ; HIV-1 - immunology ; HLA-B Antigens - genetics ; HLA-B Antigens - physiology ; HLA-B51 Antigen ; Human immunodeficiency virus 1 ; Humans ; Immunodominant Epitopes - genetics ; Immunodominant Epitopes - immunology ; Mutation ; pol Gene Products, Human Immunodeficiency Virus - genetics ; pol Gene Products, Human Immunodeficiency Virus - immunology ; T-Lymphocytes, Cytotoxic - immunology ; T-Lymphocytes, Cytotoxic - pathology ; T-Lymphocytes, Cytotoxic - virology</subject><ispartof>The Journal of immunology (1950), 2011-07, Vol.187 (2), p.684-691</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-35d125593748970fe70ada4ca8e82ff60478385d5ec7ad128d8aebc72844a1043</citedby><cites>FETCH-LOGICAL-c493t-35d125593748970fe70ada4ca8e82ff60478385d5ec7ad128d8aebc72844a1043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21670313$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, YongHong</creatorcontrib><creatorcontrib>Peng, YanChun</creatorcontrib><creatorcontrib>Yan, HuiPing</creatorcontrib><creatorcontrib>Xu, Keyi</creatorcontrib><creatorcontrib>Saito, Masumichi</creatorcontrib><creatorcontrib>Wu, Hao</creatorcontrib><creatorcontrib>Chen, XinYue</creatorcontrib><creatorcontrib>Ranasinghe, Srinika</creatorcontrib><creatorcontrib>Kuse, Nozomi</creatorcontrib><creatorcontrib>Powell, Tim</creatorcontrib><creatorcontrib>Zhao, Yan</creatorcontrib><creatorcontrib>Li, WeiHua</creatorcontrib><creatorcontrib>Zhang, Xin</creatorcontrib><creatorcontrib>Feng, Xia</creatorcontrib><creatorcontrib>Li, Ning</creatorcontrib><creatorcontrib>Leligdowicz, Aleksandra</creatorcontrib><creatorcontrib>Xu, XiaoNing</creatorcontrib><creatorcontrib>John, Mina</creatorcontrib><creatorcontrib>Takiguchi, Masafumi</creatorcontrib><creatorcontrib>McMichael, Andrew</creatorcontrib><creatorcontrib>Rowland-Jones, Sarah</creatorcontrib><creatorcontrib>Dong, Tao</creatorcontrib><title>Multilayered defense in HLA-B51-associated HIV viral control</title><title>The Journal of immunology (1950)</title><addtitle>J Immunol</addtitle><description>Polymorphism in the HLA region of a chromosome is the major source of host genetic variability in HIV-1 outcome, but there is limited understanding of the mechanisms underlying the beneficial effect of protective class I alleles such as HLA-B57, -B27, and -B51. Taking advantage of a unique cohort infected with clade B' HIV-1 through contaminated blood, in which many variables such as the length of infection, the infecting viral strain, and host genetic background are controlled, we performed a comprehensive study to understand HLA-B51-associated HIV-1 control. We focused on the T cell responses against three dominant HLA-B51-restricted epitopes: Gag327-345(NI9) NANPDCKTI, Pol743-751(LI9) LPPVVAKEI, and Pol283-289(TI8) TAFTIPSI. Mutations in all three dominant epitopes were significantly associated with HLA-B51 in the cohort. A clear hierarchy in selection of epitope mutations was observed through epitope sequencing. L743I in position 1 of epitope LI9 was seen in most B51(+) individuals, followed by V289X in position 8 of the TI8, and then, A328S, in position 2 of the NI9 epitope, was also seen in some B51(+) individuals. Good control of viral load and higher CD4(+) counts were significantly associated with at least one detectable T cell response to unmutated epitopes, whereas lower CD4(+) counts and higher viral loads were observed in patients who had developed escape mutations in all three epitopes or who lacked T cell responses specific to these epitope(s). We propose that patients with HLA-B51 benefit from having multiple layers of effective defense against the development of immune escape mutations.</description><subject>Clone Cells</subject><subject>Cohort Studies</subject><subject>Cytotoxicity, Immunologic - genetics</subject><subject>Epitopes, T-Lymphocyte - genetics</subject><subject>Epitopes, T-Lymphocyte - immunology</subject><subject>gag Gene Products, Human Immunodeficiency Virus - genetics</subject><subject>gag Gene Products, Human Immunodeficiency Virus - immunology</subject><subject>HEK293 Cells</subject><subject>HIV-1 - genetics</subject><subject>HIV-1 - immunology</subject><subject>HLA-B Antigens - genetics</subject><subject>HLA-B Antigens - physiology</subject><subject>HLA-B51 Antigen</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>Immunodominant Epitopes - genetics</subject><subject>Immunodominant Epitopes - immunology</subject><subject>Mutation</subject><subject>pol Gene Products, Human Immunodeficiency Virus - genetics</subject><subject>pol Gene Products, Human Immunodeficiency Virus - immunology</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>T-Lymphocytes, Cytotoxic - pathology</subject><subject>T-Lymphocytes, Cytotoxic - virology</subject><issn>0022-1767</issn><issn>1550-6606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkTtPwzAUhS0EoqWwM6FsTCnX8TMSQioIaKUiFmC1XMcBV05c4gSp_56gPgQT0x3Od899HITOMYwp0Pxq6aqqq4MfYwxAMD9AQ8wYpJwDP0RDgCxLseBigE5iXAIAh4weo0GGueh5MkTXT51vnddr29giKWxp62gTVyfT-SS9ZTjVMQbjdNur09lb8uUa7RMT6rYJ_hQdldpHe7atI_T6cP9yN03nz4-zu8k8NTQnbUpYgTPGciKozAWUVoAuNDVaWpmVJQcqJJGsYNYI3aOykNoujMgkpRoDJSN0s_FddYvKFsb207VXq8ZVulmroJ36q9TuQ72HL9W_hEsGvcHl1qAJn52NrapcNNZ7XdvQRZUDpQJ4Rv8lpWACS0JFT8KGNE2IsbHlfh8M6icdtUtHbdPpWy5-37Fv2MVBvgHSnYwh</recordid><startdate>20110715</startdate><enddate>20110715</enddate><creator>Zhang, YongHong</creator><creator>Peng, YanChun</creator><creator>Yan, HuiPing</creator><creator>Xu, Keyi</creator><creator>Saito, Masumichi</creator><creator>Wu, Hao</creator><creator>Chen, XinYue</creator><creator>Ranasinghe, Srinika</creator><creator>Kuse, Nozomi</creator><creator>Powell, Tim</creator><creator>Zhao, Yan</creator><creator>Li, WeiHua</creator><creator>Zhang, Xin</creator><creator>Feng, Xia</creator><creator>Li, Ning</creator><creator>Leligdowicz, Aleksandra</creator><creator>Xu, XiaoNing</creator><creator>John, Mina</creator><creator>Takiguchi, Masafumi</creator><creator>McMichael, Andrew</creator><creator>Rowland-Jones, Sarah</creator><creator>Dong, Tao</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20110715</creationdate><title>Multilayered defense in HLA-B51-associated HIV viral control</title><author>Zhang, YongHong ; Peng, YanChun ; Yan, HuiPing ; Xu, Keyi ; Saito, Masumichi ; Wu, Hao ; Chen, XinYue ; Ranasinghe, Srinika ; Kuse, Nozomi ; Powell, Tim ; Zhao, Yan ; Li, WeiHua ; Zhang, Xin ; Feng, Xia ; Li, Ning ; Leligdowicz, Aleksandra ; Xu, XiaoNing ; John, Mina ; Takiguchi, Masafumi ; McMichael, Andrew ; Rowland-Jones, Sarah ; Dong, Tao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-35d125593748970fe70ada4ca8e82ff60478385d5ec7ad128d8aebc72844a1043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Clone Cells</topic><topic>Cohort Studies</topic><topic>Cytotoxicity, Immunologic - genetics</topic><topic>Epitopes, T-Lymphocyte - genetics</topic><topic>Epitopes, T-Lymphocyte - immunology</topic><topic>gag Gene Products, Human Immunodeficiency Virus - genetics</topic><topic>gag Gene Products, Human Immunodeficiency Virus - immunology</topic><topic>HEK293 Cells</topic><topic>HIV-1 - genetics</topic><topic>HIV-1 - immunology</topic><topic>HLA-B Antigens - genetics</topic><topic>HLA-B Antigens - physiology</topic><topic>HLA-B51 Antigen</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>Immunodominant Epitopes - genetics</topic><topic>Immunodominant Epitopes - immunology</topic><topic>Mutation</topic><topic>pol Gene Products, Human Immunodeficiency Virus - genetics</topic><topic>pol Gene Products, Human Immunodeficiency Virus - immunology</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>T-Lymphocytes, Cytotoxic - pathology</topic><topic>T-Lymphocytes, Cytotoxic - virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, YongHong</creatorcontrib><creatorcontrib>Peng, YanChun</creatorcontrib><creatorcontrib>Yan, HuiPing</creatorcontrib><creatorcontrib>Xu, Keyi</creatorcontrib><creatorcontrib>Saito, Masumichi</creatorcontrib><creatorcontrib>Wu, Hao</creatorcontrib><creatorcontrib>Chen, XinYue</creatorcontrib><creatorcontrib>Ranasinghe, Srinika</creatorcontrib><creatorcontrib>Kuse, Nozomi</creatorcontrib><creatorcontrib>Powell, Tim</creatorcontrib><creatorcontrib>Zhao, Yan</creatorcontrib><creatorcontrib>Li, WeiHua</creatorcontrib><creatorcontrib>Zhang, Xin</creatorcontrib><creatorcontrib>Feng, Xia</creatorcontrib><creatorcontrib>Li, Ning</creatorcontrib><creatorcontrib>Leligdowicz, Aleksandra</creatorcontrib><creatorcontrib>Xu, XiaoNing</creatorcontrib><creatorcontrib>John, Mina</creatorcontrib><creatorcontrib>Takiguchi, Masafumi</creatorcontrib><creatorcontrib>McMichael, Andrew</creatorcontrib><creatorcontrib>Rowland-Jones, Sarah</creatorcontrib><creatorcontrib>Dong, Tao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of immunology (1950)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, YongHong</au><au>Peng, YanChun</au><au>Yan, HuiPing</au><au>Xu, Keyi</au><au>Saito, Masumichi</au><au>Wu, Hao</au><au>Chen, XinYue</au><au>Ranasinghe, Srinika</au><au>Kuse, Nozomi</au><au>Powell, Tim</au><au>Zhao, Yan</au><au>Li, WeiHua</au><au>Zhang, Xin</au><au>Feng, Xia</au><au>Li, Ning</au><au>Leligdowicz, Aleksandra</au><au>Xu, XiaoNing</au><au>John, Mina</au><au>Takiguchi, Masafumi</au><au>McMichael, Andrew</au><au>Rowland-Jones, Sarah</au><au>Dong, Tao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multilayered defense in HLA-B51-associated HIV viral control</atitle><jtitle>The Journal of immunology (1950)</jtitle><addtitle>J Immunol</addtitle><date>2011-07-15</date><risdate>2011</risdate><volume>187</volume><issue>2</issue><spage>684</spage><epage>691</epage><pages>684-691</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><abstract>Polymorphism in the HLA region of a chromosome is the major source of host genetic variability in HIV-1 outcome, but there is limited understanding of the mechanisms underlying the beneficial effect of protective class I alleles such as HLA-B57, -B27, and -B51. Taking advantage of a unique cohort infected with clade B' HIV-1 through contaminated blood, in which many variables such as the length of infection, the infecting viral strain, and host genetic background are controlled, we performed a comprehensive study to understand HLA-B51-associated HIV-1 control. We focused on the T cell responses against three dominant HLA-B51-restricted epitopes: Gag327-345(NI9) NANPDCKTI, Pol743-751(LI9) LPPVVAKEI, and Pol283-289(TI8) TAFTIPSI. Mutations in all three dominant epitopes were significantly associated with HLA-B51 in the cohort. A clear hierarchy in selection of epitope mutations was observed through epitope sequencing. L743I in position 1 of epitope LI9 was seen in most B51(+) individuals, followed by V289X in position 8 of the TI8, and then, A328S, in position 2 of the NI9 epitope, was also seen in some B51(+) individuals. Good control of viral load and higher CD4(+) counts were significantly associated with at least one detectable T cell response to unmutated epitopes, whereas lower CD4(+) counts and higher viral loads were observed in patients who had developed escape mutations in all three epitopes or who lacked T cell responses specific to these epitope(s). We propose that patients with HLA-B51 benefit from having multiple layers of effective defense against the development of immune escape mutations.</abstract><cop>United States</cop><pmid>21670313</pmid><doi>10.4049/jimmunol.1100316</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-1767 |
ispartof | The Journal of immunology (1950), 2011-07, Vol.187 (2), p.684-691 |
issn | 0022-1767 1550-6606 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3166850 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Clone Cells Cohort Studies Cytotoxicity, Immunologic - genetics Epitopes, T-Lymphocyte - genetics Epitopes, T-Lymphocyte - immunology gag Gene Products, Human Immunodeficiency Virus - genetics gag Gene Products, Human Immunodeficiency Virus - immunology HEK293 Cells HIV-1 - genetics HIV-1 - immunology HLA-B Antigens - genetics HLA-B Antigens - physiology HLA-B51 Antigen Human immunodeficiency virus 1 Humans Immunodominant Epitopes - genetics Immunodominant Epitopes - immunology Mutation pol Gene Products, Human Immunodeficiency Virus - genetics pol Gene Products, Human Immunodeficiency Virus - immunology T-Lymphocytes, Cytotoxic - immunology T-Lymphocytes, Cytotoxic - pathology T-Lymphocytes, Cytotoxic - virology |
title | Multilayered defense in HLA-B51-associated HIV viral control |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T09%3A59%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multilayered%20defense%20in%20HLA-B51-associated%20HIV%20viral%20control&rft.jtitle=The%20Journal%20of%20immunology%20(1950)&rft.au=Zhang,%20YongHong&rft.date=2011-07-15&rft.volume=187&rft.issue=2&rft.spage=684&rft.epage=691&rft.pages=684-691&rft.issn=0022-1767&rft.eissn=1550-6606&rft_id=info:doi/10.4049/jimmunol.1100316&rft_dat=%3Cproquest_pubme%3E875718347%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=875718347&rft_id=info:pmid/21670313&rfr_iscdi=true |